| Title |
Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study
|
|---|---|
| Published in |
Annals of Surgical Oncology, May 2017
|
| DOI | 10.1245/s10434-017-5897-0 |
| Pubmed ID | |
| Authors |
C. Bisschop, T. H. van Dijk, J. C. Beukema, R. L. H. Jansen, H. Gelderblom, K. P. de Jong, H. J. T. Rutten, C. J. H. van de Velde, T. Wiggers, K. Havenga, G. A. P. Hospers |
| Abstract |
In a Dutch phase II trial conducted between 2006 and 2010, short-course radiotherapy followed by systemic therapy with capecitabine, oxaliplatin, and bevacizumab as neoadjuvant treatment and subsequent radical surgical treatment of primary tumor and metastatic sites was evaluated. In this study, we report the long-term results after a minimum follow-up of 6 years. Patients with histologically confirmed rectal adenocarcinoma with potentially resectable or ablatable metastases in liver or lungs were eligible. Follow-up data were collected for all patients enrolled in the trial. Overall and recurrence-free survival were calculated using the Kaplan-Meier method. Follow-up data were available for all 50 patients. After a median follow-up time of 8.1 years (range 6.0-9.8), 16 patients (32.0%) were still alive and 14 (28%) were disease-free. The median overall survival was 3.8 years (range 0.5-9.4). From the 36 patients who received radical treatment, two (5.6%) had a local recurrence and 29 (80.6%) had a distant recurrence. Long-term survival can be achieved in patients with primary metastatic rectal cancer after neoadjuvant radio- and chemotherapy. Despite a high number of recurrences, 32% of patients were alive after a median follow-up time of 8.1 years. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Turkey | 1 | 17% |
| United Kingdom | 1 | 17% |
| Egypt | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 50% |
| Scientists | 2 | 33% |
| Members of the public | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 71 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 13% |
| Student > Ph. D. Student | 8 | 11% |
| Other | 7 | 10% |
| Professor | 6 | 8% |
| Student > Bachelor | 5 | 7% |
| Other | 17 | 24% |
| Unknown | 19 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 42% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Agricultural and Biological Sciences | 2 | 3% |
| Chemistry | 2 | 3% |
| Immunology and Microbiology | 1 | 1% |
| Other | 2 | 3% |
| Unknown | 31 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 August 2017.
All research outputs
#13,140,299
of 23,509,982 outputs
Outputs from Annals of Surgical Oncology
#3,618
of 6,656 outputs
Outputs of similar age
#148,917
of 317,175 outputs
Outputs of similar age from Annals of Surgical Oncology
#29
of 66 outputs
Altmetric has tracked 23,509,982 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,656 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,175 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.